Out in open

The more, the merrier. Join and conjoin!

Tuesday, July 10, 2007

Celebrex Competition

Celebrex Competition

The biggest challenger to Celebrex in the COX-2 inhibitor wars was Vioxx, as recent as a few years ago.  Unfortunately for Merck & Company, Vioxx sales were torpedoed in 2004, when the results of studies linked the drug to an increase in cardiovascular disease. The drug was later voluntarily removed from the market by Merck. While being sued by many consumers over the controversy, the company has been back pedaling ever since.  In the meanwhile, Celebrex has become th! e drug of choice, in the race for top COX-2 Inhibitor.  However, just last month, the Swiss pharmaceutical company Novartis released some important news.  Their COX-2 inhibitor Prexige is testing well and may soon be available in the United States (the drug is already available in 55 other countries).